Quality-of-Life Assessment: The Challenge of Incorporating Quality-of-Life and Patient-Reported Outcomes into Investigative Trials and Clinical Practice

  • Richard J. Gralla
  • Patricia J. Hollen


Health professionals have come to value health-related quality of life (HRQL) as a concept for oncology. Nonetheless, HRQL is rarely found as the primary endpoint in oncology research trials even though survival differences are uncommon. Perhaps more telling is the fact that systematic HRQL evaluation is not frequently used as part of clinical decision making in the daily practice of oncology. In this chapter, practical steps are presented for selecting validated HRQL measures, and strategies are discussed to make this endpoint easier to incorporate into both clinical trials and regular practice. There are now large compendia, which are easily available via the Internet, which lists and describes HRQL measures. This access fosters acquaintance with appropriate instruments for a variety of purposes in cancer health care. With so many measures available, some guidance in choosing suitable instruments can aid in assessment and results analysis. This overview provides steps for comparing the key features and psychometric properties of HRQL measures for patients with cancer.


Psychometric Property Minimal Important Difference Cancer Clinical Trial HRQL Measure HRQL Instrument 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Karnofsky DA, Burchenal JH: (1949) The clinical evaluation of chemotherapeutic agents in cancer, in MacLeod CM (ed): Evaluation of Chemotherapeutic Agents. Symposium, Microbiology Sections, New York Academy of Medicine, New York, NY, Columbia University Press, pp 191–205Google Scholar
  2. 2.
    Johnson JR, Temple R: (1985) Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep 69:1155–1157.PubMedGoogle Scholar
  3. 3.
    Outcomes Working Group, Health Services Research Committee, American Society of Clinical Oncology. (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. Journal of Clinical Oncology, 14:671–9.Google Scholar
  4. 4.
    Donovan K, Sanson-Fisher RW, Redman S: (1989) Measuring quality of life in cancer patients. Journal of Clinical Oncology, 7:959–968.PubMedGoogle Scholar
  5. 5.
    U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research Guidance for industry: (2006) Patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health and Quality of Life Outcomes, 4: 79.CrossRefGoogle Scholar
  6. 6.
    U.S. Department of Health and Human Services (2009) FDA Center for Drug Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry, (2006) Patient-reported outcome measures: use in medical product development to support labeling claims. draft guidance. Health and Quality of Life Outcomes, 11;4–79.Google Scholar
  7. 7.
    Emery M, Perrier L, & Acquadro C, Patient-Reported Outcome and Quality of Life Instruments Database (PROQOLID): (2005) Frequently asked questions. Health and quality of life outcomes, 3,12. Retrieved from
  8. 8.
    Gralla RJ, Hollen PJ, Eberly S, & Cox C. (1995). Quality of life score predicts both response and survival in patients receiving chemotherapy for non-small cell lung cancer. 7th MASCC International Symposium, Luxembourg, September 20–23, 1995. Supportive Care in Cancer, 3 (5), 378.Google Scholar
  9. 9.
    Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham J, Kaukel E, Ruffie P, et al. (2003). Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clinical Oncology, 21: 2636–2644.CrossRefGoogle Scholar
  10. 10.
    HA Burris, MJ Moore, J Andersen, MR Green, ML Rothenberg, MR Modiano, MC Cripps, RK Portenoy, AM Storniolo, P Tarassoff, R Nelson, FA Dorr CD Stephens and DD Von Hoff. (1997). Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology, 15: 2403–2413.PubMedGoogle Scholar
  11. 11.
    Raftopoulos H, Gralla RJ, Hollen PJ, Davis BJ, Petersen JA, & Horigan JL (2010) What do patients rank as more important in quality of life (QL) and patient reported outcome (PRO) evaluation: symptoms or summative assessments? Results of a 3860 patient survey in lung, breast and prostate cancers with implications for drug development. Journal of Clinical Oncology, (abstract) In press.Google Scholar
  12. 12.
    Bergman B, Aaronson NK, Ahmedzai S, et al: The EORTC QLQ-LC13: (1994) A modular supplement to the EORTC core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 30A: 635–642.PubMedCrossRefGoogle Scholar
  13. 13.
    Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P: (1995) Reliability and validity of the Functional Assessment of Cancer Therapy – Lung (FACT-L) quality of life instrument. Lung Cancer 12:199–220.PubMedCrossRefGoogle Scholar
  14. 14.
    Hollen PJ, Gralla RJ, Kris MG, Potanovich, L et al.: (1993) Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer 29A:S51-S58.PubMedCrossRefGoogle Scholar
  15. 15.
    Earle CC, & Weeks JC, (2005). The science of quality-of-life measurement in lung cancer. In outcomes assesments in cancer(1st ed.) In J. Lipscomp, C.C. Gotay & C. Snyder (Eds.), Outcomes assessments in cancer: Measures, methods and applications (pp. 160–177). Cambridge: Cambridge University Press.Google Scholar
  16. 16.
    Simon R, & Wittes RE: (1985) Methodological guidelines for reports of clinical trials, Cancer Treat Rep 69:1–3.PubMedGoogle Scholar
  17. 17.
    Simon R, Friedman MA (1992) The design and interpretation of clinical trials. In: Perry MC (ed) The chemotherapy source book. Baltimore: Williams & Wilkins, 130–143.Google Scholar
  18. 18.
    Nunnally JC, Bernstein PH: Psychometric theory (eds). (1994) New York, NY, McGraw-Hill.Google Scholar
  19. 19.
    Landis JR, Koch GG:. (1997) The measurement of obserrer agreement for categorical data. Biometrics 33:159–174.PubMedCrossRefGoogle Scholar
  20. 20.
    Anastasi A. (1988). Psychological testing (6th ed). New York, NY, Macmillan.Google Scholar
  21. Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, & Aaronson NK. (2006). Responsiveness and minimal important differences for patient reported outcomes. Health and Quality of Life Outcomes 2006, 4:70 doi:10.1186/1477–7525–4-70; Retrieved from
  22. 22.
    Bottomley A, Gaafa R, Manegold C, Burgers S, Coens C, Legrand C, et al. (2006). Short-term treatment-related symptoms and quality of life: Results from an international randomized Phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. Journal of Clinical Oncology, 24, 1435–1442.PubMedCrossRefGoogle Scholar
  23. 23.
    Cella D, Eton TD, Fairclough DL, Bonomi P, Heyes AE, Silberman C, et al. (2009). What is a clinically meaningful change on the Functional Assessment of Cancer Therapy–Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. Journal of Clinical Epidemiology, 55 (3), 285–295.CrossRefGoogle Scholar
  24. 24.
    Hollen PJ, & Gralla RJ. (2000) Clinical vs statistical significance: Using the LCSS quality of life instrument and Karnofsky performance status (KPS) to approach the problem in patients with non-small cell lung cancer. Journal of Clinical Oncology, 19, Abstract 636.Google Scholar
  25. 25.
    Cella D, Gershon R, Lai J, & Choi S, (2007a). The future of outcomes measurement: Item banking, tailored short-forms, and computerized adaptive assessment. Quality of Life Research, 16 (Supp1), 133–41.PubMedCrossRefGoogle Scholar
  26. 26.
    Garcia SF, Cella D, Clauser SB, Flynn KE, Lai J, Reeve BB, Smith A, et al. (2007). Standardizing patient-reported outcomes assessment in cancer clinical trials: A patient-reported ­outcomes measurement information system initiative. Journal of Clinical Oncology, 25, 5106–12.PubMedCrossRefGoogle Scholar
  27. 27.
    Hollen PJ, Gralla RJ, & Rittenberg CN. (2004). Quality of life as a clinical trial endpoint: Determining the appropriate interval for repeated assessments in patients with advanced lung cancer. Supportive Care in Cancer, 12, 767–773.PubMedCrossRefGoogle Scholar
  28. 28.
    Liepa AM, Hollen PJ, Gralla RJ, & Rusthoven JJ. (2002) Does Timing of QOL Evaluation Make a Difference? Using the Lung Cancer Symptom Scale (LCSS) Modified for Mesothelioma as an Example. 9th Annual Meeting of the International Society for Quality of Life Research, Orlando, FL, October 30-November 2, 2002.Google Scholar
  29. 29.
    Fairclough DL, Peterson FH, Chang V. (1998) Why are missing quality of life data a problem in clinical trials of cancer therapy? Stat Med 17: 667–677PubMedCrossRefGoogle Scholar
  30. 30.
    Hollen PJ, Gralla RJ, Cox C, Eberly SW, & Kris MG. (1997). A dilemma in analysis: Issues in the serial measurement of quality of life in patients with advanced lung cancer. Lung Cancer, 18, 119–136.PubMedCrossRefGoogle Scholar
  31. 31.
    Morris J, Perez D, McNoe B: The use of quality of life data in clinical practice. (1998) Quality of Life Research 7, 85–91. Google Scholar
  32. 32.
    Gralla RJ, Hollen PJ, Leighl NB, Meharchand JM, Krieger H, & Solow, H. (2006) A prospective evaluation of the attitudes of patients, physicians and nurses after using a computer-assisted quality of life instrument (LCSS-QL) as part of a multicenter clinical trial in Non-Small Cell Lung Cancer (NSCLC). Journal of Clinical Oncology, 24, 18S, Abstract 6123.Google Scholar
  33. 33.
    de Marinis F, Rodrigues J, Pereira JR, Fossella F, Perry MC, Reck M, Salzberg M, Jassem J, Peterson P, Liepa AM, Moore P, & Gralla RJ (2008). Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: An analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer. Journal of Thoracic Oncology; 3:30–36.CrossRefGoogle Scholar

Copyright information

© Society for Imaging Informatics in Medicine 2010

Authors and Affiliations

  1. 1.Division of Medical Oncology and HematologyHofstra North Shore-LIJ School of MedicineLake SuccessUSA

Personalised recommendations